Do Hyun Jung1,2, Sang Yong Son1,3, Aung Myint Oo1,4, Young Suk Park1, Dong Joon Shin1, Sang-Hoon Ahn1,5, Do Joong Park1,5, Hyung-Ho Kim6,7. 1. Department of Surgery, Seoul National University Bundang Hospital, 300 Gumi-dong, Bundang-gu, Seongnam-si, Gyenggi-do, Seoul, 463-707, Korea. 2. Department of Surgery, Korea University College of Medicine, Seoul, Korea. 3. Department of Surgery, Ajou University School of Medicine, Suwon, Korea. 4. Department of General Surgery, Tan Tock Seng Hospital, Novena, Singapore. 5. Department of Surgery, Seoul National University College of Medicine, Seoul, Korea. 6. Department of Surgery, Seoul National University Bundang Hospital, 300 Gumi-dong, Bundang-gu, Seongnam-si, Gyenggi-do, Seoul, 463-707, Korea. hhkim@snubh.org. 7. Department of Surgery, Seoul National University College of Medicine, Seoul, Korea. hhkim@snubh.org.
Abstract
BACKGROUND: Peritoneal carcinomatosis is an unmet therapeutic need. Several types of intraperitoneal chemotherapy have been introduced. However, hyperthermic intraperitoneal chemotherapy has limited drug distribution and poor peritoneal penetration. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) does not have the benefits of hyperthermia. We developed a device to apply hyperthermic PIPAC (H-PAC) and evaluated its feasibility in a porcine model. METHODS: The device for H-PAC consisted of a laparoscopic aerosol spray and a heater to create hyperthermic capnoperitoneum. We operated on five pigs for the development of the new device and on another five pigs as a survival model. After a pilot experiment of the survival model (Pig A), a hyperthermic pressurized intraperitoneal aerosol of indocyanine green was administered after insertion of three trocars (Pig B) and laparoscopy-assisted distal gastrectomy (LADG) (Pig C) without chemotherapeutic agents. After that, H-PAC with cisplatin was administered after insertion of three trocars (Pig D) and LADG (Pig E). Autopsies were performed on postoperative day 7. RESULTS: Median operation time was 85 min (80-110 min). Intraperitoneal temperature was constant for 1 h of H-PAC (38.8-40.2 °C). All five pigs were healthy and survived for 7 days. Median weight loss was 0.2 kg. Autopsy tissues of stomach, peritoneum, and jejunum were intact in all five pigs. CONCLUSIONS: H-PAC was feasible and safe in a porcine model.
BACKGROUND:Peritoneal carcinomatosis is an unmet therapeutic need. Several types of intraperitoneal chemotherapy have been introduced. However, hyperthermic intraperitoneal chemotherapy has limited drug distribution and poor peritoneal penetration. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) does not have the benefits of hyperthermia. We developed a device to apply hyperthermic PIPAC (H-PAC) and evaluated its feasibility in a porcine model. METHODS: The device for H-PAC consisted of a laparoscopic aerosol spray and a heater to create hyperthermic capnoperitoneum. We operated on five pigs for the development of the new device and on another five pigs as a survival model. After a pilot experiment of the survival model (Pig A), a hyperthermic pressurized intraperitoneal aerosol of indocyanine green was administered after insertion of three trocars (Pig B) and laparoscopy-assisted distal gastrectomy (LADG) (Pig C) without chemotherapeutic agents. After that, H-PAC with cisplatin was administered after insertion of three trocars (Pig D) and LADG (Pig E). Autopsies were performed on postoperative day 7. RESULTS: Median operation time was 85 min (80-110 min). Intraperitoneal temperature was constant for 1 h of H-PAC (38.8-40.2 °C). All five pigs were healthy and survived for 7 days. Median weight loss was 0.2 kg. Autopsy tissues of stomach, peritoneum, and jejunum were intact in all five pigs. CONCLUSIONS:H-PAC was feasible and safe in a porcine model.
Authors: Pedro Antonio Cascales-Campos; J Gil; E Gil; E Feliciangeli; A González-Gil; J J Parrilla; P Parrilla Journal: Ann Surg Oncol Date: 2014-03-06 Impact factor: 5.344
Authors: Wiebke Solass; Reinhold Kerb; Thomas Mürdter; Urs Giger-Pabst; Dirk Strumberg; Clemens Tempfer; Jürgen Zieren; Matthias Schwab; Marc André Reymond Journal: Ann Surg Oncol Date: 2013-09-05 Impact factor: 5.344
Authors: Veria Khosrawipour; David Diaz-Carballo; Ali-Haydar Acikelli; Tanja Khosrawipour; Thomas Albert Falkenstein; Dan Wu; Jürgen Zieren; Urs Giger-Pabst Journal: World J Surg Oncol Date: 2017-02-10 Impact factor: 2.754
Authors: C Bachmann; I Sautkin; G Nadiradze; R Archid; F J Weinreich; A Königsrainer; M A Reymond Journal: Surg Endosc Date: 2021-06-10 Impact factor: 4.584